000 06211cam a2200589Ki 4500
001 9781315150710
003 FlBoTFG
005 20220711212137.0
006 m o d
007 cr cnu---|nuuu
008 190131s2019 flu ob 001 0 eng d
040 _aOCoLC-P
_beng
_erda
_epn
_cOCoLC-P
020 _a9781315150710
_q(electronic bk.)
020 _a1315150719
_q(electronic bk.)
020 _a9781351366717
020 _a1351366718
020 _a9781351366700
_q(electronic bk. : EPUB)
020 _a135136670X
_q(electronic bk. : EPUB)
020 _a9781351366694
_q(electronic bk. : Mobipocket)
020 _a1351366696
_q(electronic bk. : Mobipocket)
020 _z9781138557161
020 _z1138557161
035 _a(OCoLC)1083671323
035 _a(OCoLC-P)1083671323
050 4 _aQP552.M47
072 7 _aSCI
_x007000
_2bisacsh
072 7 _aMED
_x008000
_2bisacsh
072 7 _aSCI
_x017000
_2bisacsh
072 7 _aSCI
_x055000
_2bisacsh
072 7 _aMMGT
_2bicssc
082 0 4 _a572/.68
_223
100 1 _aSharma, Sushil,
_cPh. D., D.M.R.I.T.,
_eauthor.
_913571
245 1 4 _aThe Charnoly body :
_ba novel biomarker of mitochondrial bioenergetics /
_cSushil Sharma.
264 1 _aBoca Raton, FL :
_bCRC Press, Taylor & Francis Group,
_c2019.
300 _a1 online resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _a"A Science Publishers book."
505 0 _aFree radical-induced compromised mitochondrial bioenergetics triggers Charnoly body formation (free radical hypothesis of charnoly body formation; stages of intracellular toxification/detoxification; biomarkers of intracelular detoxification) -- Free radical-induced molecular pathophysiology of Charnoly body and charnolosome -- Charnoly body as a novel biomarker of cell injury -- Charnoly body as a novel biomarker of compromised mitochondrial bioenergetics (biomarkers of CMB; free radical-induced CB molecular pathogenesis) -- Antioxidants prevent Charnoly body formation, augment charnolophagy, and stabilize charnolosome to enhance mitochondrial bioenergetics and intracellular detoxification (therapeutic potential of antioxidants in response to different -- Stages of a free radical attack) -- Metallothioneins inhibit charnoly body formation and confer structural and functional stability to charnolosome (therapeutic potential of metallothioneins (MTS) as CB antagonists; therapeutic potential of (MTS) as charnolosome (CS) stabilizers) -- The Charnoly body : a novel biomarker of mitochondrial bioenergetics -- Clinical significance of Charnoly body as a biomarker of compromized mitochondrial bioenergetics in multidrug resistant diseases -- Development of novel charnolopharmacotherapeutics in pharmaceutical industry by flow cytometric analysis -- Charnoly body as a novel biomarker in nanomedicine (Charnoly body, charnolophagosome, and charnlosome as potential nanotheranostic biomarkers in evidence based personalized medicine) -- Clinical significance of mitochondrial bioenergetic and Charnoly body in evidence based personalized nanotheranostics -- Translational multimodality neuroimaging of Charnoly body, charnolophagy, and charnolosome for personalized theranostics of chronic MDR diseases -- Pet radiopharmaceuticals and surface plasmon resonance spectroscopy for Charnoly body and micro-RNA based personalized theranostics -- Therapeutic potential of stem cells from different biological sources as Charnoly body anagonists, charnolophagy agonists, and charnolosome stabilizers -- Charnolopharmacotherapeutics of chronic multidrug resistant diseases by metallothionein-induced hypoxia inducible factor-1 -- Clinical significance of disease-specific Charnoly body formation -- Charnoly body in fetal alcohol syndrome -- Charnoly body in nicotinism -- Charnoly body in ZIKV disease -- Charnoly body in malnutrition -- Charnoly body in drug addiction and other chronic multi-drug-resistant diseases (therapeutic potential of MTS) -- Charnoly body in cardiovascular diseases -- Charnoly body in stroke -- Charnoly body in traumatic brain injury -- Charnolopharmacotherapy of neurodegenerative and other diseases.
520 _aDiversified physicochemical injuries trigger Charnoly body (CB) formation as pleomorphic, electron-dense, multi-lamellar stacks of nonfunctional mitochondrial membranes in the most vulnerable cell. Free radicals induce downregulation of mitochondrial DNA, microRNA, AgNOR, and epigenetics to trigger CB molecular pathogenesis. CB is eliminated by energy (ATP)-driven lysosome-dependent charnolophagy as a basic molecular mechanism of intracellular detoxification to prevent acute and chronic diseases. Accumulation of CB at the junction of axon hillock and charnolosome (CS) at the synapses causes cognitive impairments; whereas, nonspecific induction of CB causes GIT stress, myelosuppression, alopecia, neurotoxicity, cardiotoxicity, and infertility in multidrug-resistant malignancies. Hence, stem cell-specific CB, charnolophagy, and CS agonists/antagonists are introduced as novelcharnolopharmacotherapeutics for the successful treatment of cardiovascular diseases, neurodegenerative diseases, infectious diseases, drug addiction, and cancer. Nanoparticles to improve drug delivery, CS exocytosis, and disease-specific spatiotemporal charnolosomics employing correlative and combinatorial bioinformatics boost mitochondrial bioenergetics through balanced diet, exercise, and antioxidants. The book will be of interest to medical scientists and practitioners.
588 _aOCLC-licensed vendor bibliographic record.
650 0 _aMetallothionein.
_913572
650 0 _aBiochemical markers.
_911965
650 7 _aSCIENCE / Life Sciences / Biochemistry
_2bisacsh
_912308
650 7 _aMEDICAL / Biochemistry
_2bisacsh
_910709
650 7 _aSCIENCE / Life Sciences / Cytology
_2bisacsh
_910908
650 7 _aSCIENCE / Physics
_2bisacsh
_910678
856 4 0 _3Taylor & Francis
_uhttps://www.taylorfrancis.com/books/9781315150710
856 4 2 _3OCLC metadata license agreement
_uhttp://www.oclc.org/content/dam/oclc/forms/terms/vbrl-201703.pdf
942 _cEBK
999 _c70475
_d70475